Attenuated Salmonella enterica serovar Typhimurium can home to gastrointestinal tumors and directly affect the tumor epithelium, inducing transcriptional and metabolic changes that lead to reduced tumor burden in mice. 2 Abstract: Bacterial cancer therapy (BCT) shows great promise for treatment of solid tumors, yet basic mechanisms of bacterial-induced tumor suppression remain undefined. The intestinal epithelium is the natural route of infection for Salmonella and thus harbors innate immune defenses which protect against infection. Attenuated strains of Salmonella enterica serovar Typhimurium (STm) have commonly been used in mouse models of BCT, largely with the use of xenograft and orthotopic transplant cancer models. We aimed to better understand the tumor epithelium-targeted mechanisms of BCT by using mouse models of intestinal tumorigenesis and tumor organoid cultures to assess the effectiveness and mechanisms of treatment with aromatase A-deficient STm (STm ∆aroA ). STm ∆aroA delivered by oral gavage could significantly reduce tumor burden and tumor load in both a colitis-associated colon cancer model (CAC) and in a spontaneous intestinal cancer model, Apc min/+ mice. STm ∆aroA colonization of tumors caused alterations in transcription of mRNAs associated with epithelial-mesenchymal transition as well as metabolic and cell cycle-related transcripts. Metabolomic analysis of tumors demonstrated alteration in the metabolic environment of STm ∆aroA -treated tumors, suggesting STm ∆aroA imposes metabolic competition on the tumor.
Introduction
The concept of using bacteria as cancer therapeutics (bacterial cancer therapy, BCT) dates back to the late 1800's, when the field of BCT was initiated by William Coley (1) . Even earlier observations of spontaneous tumor regression following infection of patients' tumors had led Coley to treat cancer patients with injections of bacterial preparations. Despite this early work on BCT there is only one currently in the clinic; Bacillus Calmette-Guérin vaccine (BCG) therapy for superficial bladder cancer (2) . The advancement of molecular genetics and genetic engineering has enabled bacteria to be effectively attenuated to remove adverse side-effects and engineered to deliver different payloads. With this, there has been a resurgence in interest in BCT in the past 20 years, with many studies showing efficacy of attenuated bacterial treatments in xenograft and orthotopic transplant tumor models, with Salmonella enterica serovar Typhimurium (STm) being by far the most studied (3) (4) (5) (6) (7) (8) (9) . Yet despite this interest, very little is understood about the underlying mechanisms of BCTmediated tumor suppression, which is holding back its practical application. A few phase 1 trials have been conducted using attenuated STm strains and showed mixed results in terms of colonization and effect (10) (11) (12) . The STm strain VNP20009 was used in these trials, and when given i.v. showed poor tumor colonization and induced toxicity (10) . Another of the trials used intratumoral delivery of VNP20009, and higher tumor colonization was observed without toxicity (11) . Lack of chemotactic ability of the VNP20009 strain, due to mutation of the cheY gene, has been suggested to be a limiting factor to its success. Mouse models have shown cheY to be redundant (13) , while another has shown it to be important, for tumor localization (14) .
Despite poor translation into the clinic as yet, data from mouse models, as well as Coley's work and the use of BCG therapy, does suggest promise for BCTs. Attenuated STm are extremely tumor-tropic-a therapy that can give such tumor tissue selectivity is very desirable and enables further engineering to deliver drugs, immune adjuvants or other anti-tumor agents (3) . Therefore, further investigation and understanding is warranted. Tumor tissue tropism of attenuated bacteria is thought to be driven by the lack of immune detection within tumors and also the metabolic environment. A benefit of using STm is that it is a facultative anaerobe, which means it can reside in both anoxic and aerobic regions of tumor.
Recruitment and/or retainment of STm in the tumor environment has been suggested to be driven by availability of metabolites. High levels of aspartate, serine, ribose/galactose and ethanolamine have been shown to play a role in different in vitro and in vivo cancer models (14, 15) . The role of chemotaxis is contested, with results suggesting it to be both important and redundant (13, 14, 16) . Crull et al (16) hypothesized that tumor invasion in vivo is more passive than in vitro, as the resulting chemokine and cytokine release upon i.v. or i.p. delivery of STm would open tumor vasculature enabling delivery of bacteria to the tumor. Therefore, the delivery route and tumor type might account for varying results. It appears that invasion of tumor cells is not necessary for anti-tumor effects, as mutants of invasion genes (eg. SPI-1 and SPI-2) are equally good at invading tumor tissue and inducing tumor regression (14, 16) . One study showed the formation of STm biofilms within tumors, which was important for their anti-tumor effects (17) . It may well be that the tumor model and mode of delivery play a large role in the requirements of STm, or other bacteria, to home to tissue.
BCT is assumed to exert its effect by eliciting an immune response. Yet there isn't a clear understanding of immune-mediated events, whether an immune response is elicited to the bacteria, or to tumor cells. It is thought that attenuated STm, or other bacteria, can survive within tumors because there is poor immune response (3) . Effective treatment with STm has been observed in adaptive immune-deficient (nude) mouse models (8, 18) , suggesting that T cell responses may not be essential for anti-tumor effects. In some studies that have assessed immune infiltrates, only STm or E. coli that were engineered to deliver an immunestimulatory product elicited a significant immune response (19, 20) . Other studies have shown induction of an immune response, such as induction of IL-1b and TNF-a when delivered i.v. (21, 22) or increased neutrophil and CD8 T cell recruitment when delivered orally (9) to mice bearing subcutaneous tumors (CT26 or MC38 colorectal tumors). So, whilst there is some evidence of changes in tumor immune responses following BCT, it is not yet known whether this is key to the anti-tumor effects of BCT.
The hypothesis that we aimed to explore here is that BCT can have a direct effect on the tumor epithelial cells. Interestingly, the only current BCT in the clinic, BCG used for superficial bladder cancer (2) , is delivered intravesically directly to the bladder epithelium, which might be important for its success. Studies on BCT so far have utilized xenograft or orthotopic transplant models of cancer, which may not fully model complex disease in patients and therefore not inform on the mechanisms of BCT. Driven by an interest in intestinal epithelial innate immune pathways that protect epithelial cells from STm infection and tumorigenesis (24, 25) , we aimed to determine if STm treatment could be effective for treating autochthonous tumors of the intestine. We reasoned that since STm naturally infects via the intestine, that intestinal cancer would be a good model to use, and that treating colorectal cancer (CRC) patients by oral delivery of attenuated STm would be feasible, since oral vaccines for S. typhi are widely used and tolerated (26) . Oral delivery of STm may also avoid problems of tumor homing and toxicity that have been observed when delivering STm i.v. to patients (10) . Using a model of colitis-associated cancer (CAC) and a spontaneous model of intestinal cancer, Apc min/+ mice, we showed that oral delivery of an attenuated STm reduces tumor burden. Transcriptomic and metabolomic analysis, coupled with use of tumor organoids in vitro, demonstrated effects of STm on the tumor epithelium, and found that metabolic competition was a likely driver of anti-tumor effects.
Results

Orally-administered aromatase-A-deficient STm reduces gastrointestinal tumor burden
We utilized STm deficient for aromatase A (STm ∆aroA ) (UF020 (27) ) to assess whether BCT could be effective for treating murine autochthonous gastrointestinal tumors (colon or small intestine (SI)). We first induced colon tumors in C57B6/J mice using a well-described model of colitis-associated cancer (CAC), which has 100% penetrance (25, 28) (Fig. 1A) . After tumor induction, mice were then split into treatment groups, ensuring equivalent colitis severity between groups. Fig. S1 shows weight loss during the AOM/DSS protocol. After recovery from the final dose of DSS, mice were given 5x10 9 CFU STm ∆aroA , or vehicle control, by oral gavage once per week for 6 weeks. After 6 weeks treatment, tumor burden was assessed and compared to that of control-treated mice and to mice sacrificed at the start of the STm ∆aroA treatment protocol (denoted D0) ( Fig. 1A) . Tumor burden and tumor load was significantly decreased in STm ∆aroA -treated mice, compared to D0 and 6-week controltreated mice (Fig. 1B) . This indicates that STm ∆aroA treatment by oral delivery could reduce existing tumor burden and prevent further tumor development or growth.
Next, we tested STm ∆aroA treatment in Apc min/+ mice. These mice carry a mutation in the adenomatous polyposis coli gene (Apc) which results in multiple intestinal neoplasia (min), serving as a model of human familial adenomatous polyposis (FAP). Though, in mice the Apc mutation results largely in small intestinal (SI) neoplasia, and not colonic neoplasia. We treated Apc min/+ mice with 5x10 9 CFU STm ∆aroA by oral gavage once per week for 10 weeks, from 8 weeks of age ( Fig. 1C) . At this age, the SI has already developed a large number of polyps and they continue to grow in size, with mice at 18 weeks showing large welldeveloped polyps throughout the SI tract. Treatment of Apc min/+ mice with STm ∆aroA substantially reduced the tumor burden and tumor size ( Fig. 1D ). 
STm ∆aroA specifically localize in tumor tissue
Attenuated strains of STm preferentially home to tumor tissues and not to normal healthy tissues (4-9) and hence do not cause overt disease in recipient mice. We confirmed that STm ∆aroA could be re-isolated from tumor tissue, but not from normal healthy tissue surrounding the tumors in both the CAC and Apc min/+ models ( Fig. 1E and F, respectively) .
Further, we checked whether STm ∆aroA could disseminate to peripheral organs 24 hours after infection of Apc min/+ mice and could find very few or no CFU in the blood, MLN, liver or spleen ( Fig. S2) .
We next employed scanning electron microscopy (SEM) to view bacterial colonization in greater detail. We found exceptionally large colonies of STm ∆aroA within the tumor mass just 24 hrs after administration ( Fig. 2, see insets) . The large size of the bundles suggest that they were rapidly dividing within the tumor extracellular spaces. We could also find instances of single or a few bacteria ( Fig. 2 , red arrows). No bacteria could be observed in non-treated mice ( Fig. S3 ), suggesting that normal microbiota are not able to penetrate tumor tissue to form mass colonies as observed with the STm ∆aroA . Immunohistochemistry detecting mCherry-expressing STm ∆aroA further supports the SEM data showing large colonies of STm ∆aroA (Fig. S3 ).
Figure 2: Scanning electron microscopy of STm ∆aroA -treated tumors.
Mice bearing CAC colon tumors were given STm ∆aroA or control vehicle by oral gavage and tissues were taken 24 hours later. Whole sections of colon with tumors were prepared for SEM by glutaraldehyde fixation, dehydration and freeze drying. Tumors were cut on the sagittal plane and mounted for platinum-coating and SEM imaging. Top image shows lower magnification view of a tumor area. Luminal side indicates the top of the tumor that was facing the intestinal lumen and muscularis side indicates the inner side of tumor reaching the lamina propria and muscularis mucosa. Small red arrows indicate small STm ∆aroA colonies or individual bacteria. Large black arrows indicate areas shown in higher magnification shown below.
STm ∆aroA alters the transcriptional landscape of tumors
Next, to gain an understanding of the differences between non-treated and STm ∆aroA -treated tumors, we performed RNA sequencing on RNA isolated from whole tumor homogenates.
Tumor (T) and adjacent normal (N) tissue was dissected from AOM/DSS-induced CACbearing mice after 4 weeks treatment. First, we identified the transcripts that were differentially regulated between N and T tissue in the non-treated and STm ∆aroA -treated groups. Fig 3A shows the number of overlapping and unique genes for each treatment. These differentially-expressed genes (DEGs) were then analyzed by gene ontology (GO) analysis using DAVID (29, 30) , revealing terms enriched in either the non-treated tumors or in the treated tumors, which intriguingly were vastly different ( Fig. 3B) . As expected, non-treated tumors exhibited enrichment of mRNAs involved in cell cycle processes, mitosis, cell division, DNA repair etc., whereas, STm ∆aroA -treated tumors displayed enrichment of mRNAs for processes involving regulation of mesenchymal cell proliferation, mesenchymal-epithelial cell signaling, as well as regulation of blood vessel development, amongst other pathways.
( Fig. 3B, Fig. S4 ). Several genes involved in DNA repair, DNA damage response, RNA synthesis and epithelial-mesenchymal transition were significantly reduced following STm ∆aroA treatment ( Fig. S4) , which suggest a change in rate of cell proliferation. We decided to concentrate on stem cell, EMT and metabolism-related genes, and confirmed a selection of targets by qPCR in independent experiments. As previously reported, transcripts for epithelial stem cells, proliferation or epithelial-to-mesenchymal transition-related processes, including Lgr5 (leucine-rich repeat-containing G-protein coupled receptor), Smoc2 (SPARC related modular calcium binding 2), Vim (Vimentin), Ccnd1 (Cyclin D1) and Pdk4 (pyruvate dehydrogenase kinase 4) (31-37) were increased in tumor tissue when compared to normal tissue ( Fig. 4A) .
Strikingly, these transcripts were largely decreased following STm ∆aroA treatment ( Fig. 4A) .
We confirmed these mRNA changes in the Apc min/+ model, comparing tumor tissue from nontreated and STm ∆aroA treatment. In line with results from the CAC model, STm ∆aroA treatment altered the transcriptional levels of the above-mentioned genes and additional EMT-related genes Twist and Snail (Fig. 4B) . Loss of E-cadherin protein at the cell-cell junctions is an important feature of EMT, therefore we checked E-cadherin protein expression and localization by immunofluorescent staining of sections taken from CAC tumor-bearing mice.
Non-treated tumor sections showed very little E-cadherin protein; and where it was present it was cytosolic staining (Fig. 4C) . In contrast, tumors from STm ∆aroA treated mice showed significant levels of cell membrane localized E-cadherin ( Fig. 4C) . Thus it appears that STm ∆aroA treatment diminishes tumors and restores epithelial identity. This likely reflects that STm ∆aroA treatment is having a direct effect on tumor cells as well as the fact that tumors are diminished in size and normal epithelium is restored. 
STm ∆aroA alters the metabolic environment of tumors
Previous studies have demonstrated that that BCT can affect tumor growth by utilizing excess nutrients, such as ethanolamine (14) , or are attracted to tumors due to high levels of metabolites, such as ribose or leucine (15) . Our observation of large intra-tumoral, extracellular STm ∆aroA colonies led us to question whether the tumor metabolome would be altered following treatment, as the bacteria would be competing for metabolites within the tumor environment. Tumor and normal tissue from non-treated or STm ∆aroA -treated CACtumor bearing mice after 6 weeks or 24 hours treatment were analyzed by GC-MS for polarmetabolites. Unit variance (UV) scaled GC-MS data was analyzed, and Orthogonal Partial Least Squares-Discriminant Alanysis (OPLS-DA) plots revealed a separation between nontreated and treated tumors after 6 weeks and also within 24 hours ( Fig. 5A, B respectively) (6 weeks treatment in vivo: R 2 = 0.99; Q 2 = 0.52; 24 hours treatment in vivo: R 2 = 0.99; Q 2 = 0.67). We performed pathway analysis on metabolites with a variable importance on the projection (VIP) score greater than 1 using MetaboAnalyst 3.0 (3, 4) (Tables S1 and S2 show the complete list). Common pathways affected by STm ∆aroA treatment at both timepoints (6 hours and 24 hrs) included glycine, serine and threonine metabolism, arginine and proline metabolism and citric acid cycle, amongst others ( Fig. 5C,D) . As previously described (40), many metabolites, and particularly amino acids and tricarboxylic acid (TCA) cycle intermediates, are increased in tumor tissue compared to normal tissue ( Fig. 5E, Fig. S5 &   6 ). This likely reflects the increased energy and anabolic requirements of tumors. Strikingly, many metabolites were decreased following STm ∆aroA treatment. Fig 5E shows metabolites detected in glycolysis and the TCA cycle, as well as amino acids. Perhaps not surprisingly, glucose was significantly reduced in STm ∆aroA treated tumors (Fig 5E) . Other glycolysis intermediates were only mildly affected, while several TCA cycle intermediates (citrate, succinate, fumarate and malate) were reduced following treatment. (Fig 5E) . Furthermore, several amino acids, which can feed different parts of the TCA cycle were reduced, including glutamate (glutamine was not detected) (Fig 5E) , which is an important fuel for glutaminolysis for which tumors can be quite dependent (41) .
Other important oncometabolites were also affected. The polyamine synthesis pathway appears affected at both 24 hours and 6 weeks post-treatment. Ornithine was reduced in STm ∆aroA treated tumors 24 hours and 6 weeks post-treatment, while putrescine was significantly affected after 6 weeks treatment and spermidine after 24 hours ( Fig. S5 & 6 ). 2hydroxyglutarate (2-HG) can accumulate in tumors due to mutant isocitrate dehydrogenase 1/2 (IDH2) activity, converting a-ketoglutarate (a-KG) to 2-HG, which can inhibit a-KGdependent dioxygenases, leading to increased histone and DNA methylation (41) . We saw increased 2-HG in CAC tumors, and this was decreased after 24 hours treatment ( Fig. 5E) .
Thus, several important fuel sources, metabolic intermediates and oncometabolites are decreased following STm ∆aroA treatment, assumedly through metabolic competition of the bacteria on the tumor cells. Tumor metabolites were assessed by GC-MS. OPLS analysis of metabolites comparing nontreated (NT) and STm ∆aroA treated tumors after (A) 6 weeks and (B) 24 hours treatment. All metabolites significantly different between STm ∆aroA treated and non-treated tumors (VIP score>1) were submitted to pathway analysis (MetaboAnalyst). Pathway analysis for 6 weeks STm ∆aroA treatment (C) and 24 hours treatment (D), represented as the percent of metabolites in a pathway that were altered, against p-value (-log). (E) Metabolites detected from glycolysis (pink shading) and TCA cycle (green shading), and amino acids (orange shading), with interrelationships depicted. X-axis are nmol/g. One-way ANOVA was performed with Bonferroni multiple comparisons test, P-values shown are the multiple comparison statistic.
STm ∆aroA directly affects tumor epithelium
Our initial hypothesis was that BCT would have a direct effect on tumor epithelium. The effects that we have described so far on tumor stem cell markers, an increase in epithelial identity, and a change in the tumor metabolome in STm ∆aroA treated tumors, suggests an impact of STm ∆aroA treatment on tumor cells. To directly test our hypothesis that STm ∆aroA treatment has a direct effect on tumor epithelium, we utilized tumor 3D organoid cultures.
We generated organoid lines from CAC-induced colorectal tumors and from Apc min/+ SI and colonic tumors. Representative images of organoid appearance is shown in Fig. S8A -C.
Tumor organoids were infected with STm ∆aroA by inoculating the culture medium (1x10 8 CFU). STm ∆aroA were able to invade the Matrigel and infect the organoids (Fig. 6A&B) . After 2 hrs infection, the culture medium was washed off and fresh medium containing gentamycin was added, so only bacteria that had infected organoids could grow, preventing any effects purely from bacterial over-growth. Organoids were then collected for analysis 24 hours after the initial infection. CFU analysis was performed to determine bacterial burden. We observe in the order of 1x10 5 CFU (Fig. 6B) per well, which contains around 1x10 6 cells within the organoid structures. Importantly, treatment of organoids with STm ∆aroA could recapitulate effects on gene expression seen in vivo, with a substantial reduction in transcripts for Lgr5, Smoc2 and Vim in both CAC-derived and Apc min/+ -derived tumor organoids, and Pdk4 in Apc min/+ organoids (expression was very low in CAC organoids) ( Fig. 6C and D) . These results provide evidence that STm ∆aroA treatment can directly affect the tumor cells, independent of effects on other systems/cell types such as the immune system. Furthermore, analysis of the organoid metabolome demonstrated separation of non-treated and treated organoids by OPLS analysis (Fig. 6E) . Taking all metabolites with a VIP score >1 (Table   S3 ) and analyzing by MetaboAnalyst revealed similarly affected metabolic pathways following in vitro STm ∆aroA treatment as for in vivo treatment, with amino acid metabolism pathways, TCA cycle and glycolysis being altered (Fig. 6F, Fig. S7) . These data suggest that bacterial colonization imposes direct metabolic competition.
To further dissect whether live bacteria are required to mediate the observed effects of STm ∆aroA on tumor organoids, or whether the presence of heat-killed bacteria or just the bacterial supernatant would be sufficient, we compared treatment of tumor organoids with live STm ∆aroA , heat-killed STm ∆aroA or STm ∆aroA supernatant (SN, prepared using 10 kDa exclusion columns). Live bacteria had the strongest effect on reducing stem cell and EMT marker expression ( Fig. 6G) . Heat-killed bacteria induced a slight reduction in Smoc2 and Vim, while STm ∆aroA SN had no effect ( Fig. 6G) , suggesting that secreted products from bacteria are not exerting these anti-tumor effects, and bacterial ligands (eg LPS) are also not driving these responses (note 10kDa filters exclude LPS, Fig. S8D ) . Furthermore, succinate, one of the metabolites identified as being reduced by STm ∆aroA treatment in vivo, was assayed and only live STm ∆aroA could induce a reduction (Fig. 6H) , thus further supporting the idea that STm ∆aroA directly impose metabolic competition. 
Discussion
Here, we present data showing that BCT can be efficacious in autochthonous models of intestinal cancer. Oral delivery of STm ∆aroA to colonic or SI tumor-bearing mice induced a reduction in tumor number and size. While the concept of using bacteria as cancer therapeutic agents is by no means novel, attempts at mechanistic understanding using in situ cancer models has not been attempted before. Previous studies have utilized orthotopic or xenograft transplant tumor models, which may not fully recapitulate complex tumor environments in spontaneously formed tumors. Therefore, to start to unpick mechanisms of BCT action, using tumor models that more faithfully recapitulate tumor development may be necessary. Apart from one BCT in the clinic (BCG used for superficial bladder cancer), trials using attenuated STm have not been successful. In a phase 1 trials, giving heavily attenuated STm intravenously resulted in poor tumor localization (10), whereas another small trial giving bacteria by intratumoral injection had better tumor localization (11) . BCG therapy is given directly onto the bladder epithelium. This suggests that the future of BCT may be where it can be applied more locally. Oral delivery of an attenuated STm would be feasible, and enable delivery directly to colonic tumors, avoiding toxicity overserved with i.v.-delivered bacteria. Proof-of principle on tolerance and safety of such treatment can be seen with S.
Typhi vaccination (26) .
Previous studies have shown that STm genes involved in ethanolamine catabolism were essential for STm survival within tumors (14) , and that STm utilize nutrient sensing pathways to localize to tumors (15) . We demonstrate that STm ∆aroA form large intra-tumoral colonies and drastically re-shape the tumor metabolome within 24 hours. Multiple metabolic pathways were affected by STm ∆aroA treatment, which would impose strong metabolic pressure on tumors cells, which would possibly make it more difficult for tumors to switch from one pathway to another to meet energy and anabolic requirements. Importantly, these biochemical effects were not seen in surrounded normal tissue. Drugging tumor metabolism is an important avenue for cancer therapy, with standard chemotherapies taking advantage of metabolic weaknesses (41) . However, not all tumors are susceptible, and side-effects from inhibiting all fast-dividing cells limits metabolic inhibitor usage. Further, some tumors are able to metabolically adapt if one pathway is blocked (41) . BCT may therefore be an avenue for introducing metabolic competition, coupling this with other metabolic inhibitors may enable lower doses of these drugs that may otherwise cause severe side-effects.
The data presented here shows bulk metabolites from tumors that contain STm ∆aroA , so we can't decipher which metabolites are bacterial-derived and which are host-derived, but the observed decrease in many metabolites from multiple pathways implies that STm ∆aroA utilize tumor-derived metabolites. Wildtype STm have been reported to utilize succinate and lactate within the intestinal environment (42, 43) , and we found a reduction of succinate in vitro only when live STm ∆aroA were present, suggesting active use of tumor metabolites by STm ∆aroA . It is possible that the metabolic competition also induces a shift in the tumor metabolism. We observed changes in Pdk4, a metabolic gene involved in inhibiting pyruvate entering into the TCA cycle. Down-regulation of this following STm ∆aroA may represent the tumor altering metabolism to reflect the change in available metabolites, or could be a result of reduction of other metabolites such as succinate, which would cause less HIF1a stabilization and reduced phosphorylation and activation of Pdk4. Importantly, we have shown here that STm ∆aroA can directly affect tumor cells, a feature that hasn't previously been appreciated. That STm ∆aroA reduced stem cell markers is promising as remaining tumor stem cells are able to form relapsing disease. Whether the effect of STm ∆aroA on stem cells marker expression was due to STm ∆aroA being more tropic for stem cells or that stem cells are more susceptible to metabolic pressure isn't yet clear. There are likely numerous concurrent adaptations occurring, and the data presented here provide some new suggestions of how BCT may be effective.
Several groups are taking the approach to BCT to engineer the bacteria to deliver drugs or other compounds that can further promote tumor death or immune clearance (19, 20, (44) (45) (46) (47) .
Given that bacteria home specifically to tumors, they are the ideal device to use to ensure tumor-specific drug targeting (3) . The data we present here shows that BCT does induce tumor regression in autochthonous models of cancer, and we show strong effects on the tumor metabolome and transcriptome. Though it is apparent that STm ∆aroA alone does not cure the mice, so further engineering of the bacteria, and/or co-therapies, are required. By understanding the mechanisms of action we could further improve the engineering of bacteria for BCT, for example delivering an engineered bacteria that can better utilize metabolites. Or unpicking how BCT affect stem cell transcripts may lead to clues on how to better target tumor stem cells. Furthermore, rational selection of tumor types and stages to be targeted, type of bacteria and attenuations, and delivery route are all likely to be important for the success of BCT. This paper demonstrates that CRC is an excellent candidate for targeting with BCT via oral delivery of attenuated STm.
Materials and Methods
Animals C57B/6J mice were purchased from JAX or CLEA (Japan). Apc min/+ mice were purchased from JAX (https://www.jax.org/strain/002020). Animal breeding was conducted under Colitis-associated cancer model C57B6/J mice were purchased at 6 weeks of age and allowed settle into the mouse facility for 1-2 weeks. Starting at 7 to 8 weeks of age, mice were given one i.p. injection of AOM (10 mg/kg, Sigma) in the afternoon. The following day, mice were given DSS (1%, MW 35 000-50 000, MP Biochemicals) in the drinking water for 5 days, followed by 16 days normal water. 2 more doses of DSS (1%) were given for 5 day periods. After the 3 rd DSS dose, mice recovered for 1 to 2 weeks before starting the STm ∆aroA treatment. 
Tissue isolation and analysis
At the end of the STm ∆aroA treatment, mice were killed and colons (CAC) or SI (Apc min/+ ) were dissected out, cut longitudinally and washed thoroughly in cold PBS. Tumors were counted under a stereo microscope using an eyepiece graticule with 10x10 mm grid. Tumors and normal tissue were then micro-dissected and either snap frozen in liquid N2 for later analysis or used for assessing bacterial colonization (CFU).
Colony forming unit analysis
Tissue was homogenized in PBS containing 0.1% triton-X using a hand-held homogenizer.
After serial dilution, 50 uL was plated onto LB agar plates containing ampicillin (200 ug/mL) and incubated at 37°C overnight. Colonies were counted and CFU calculated per gram of tissue.
Scanning electron microscopy
Colons were dissected out, cut longitudinally and thoroughly washed in PBS. Sections around 1 cm were cut and fixed in 2.5% glutaraldehyde in 0.1% phosphate buffer for 24 hours at 4°C. Tissue was then dehydrated in increasing concentration of ethanol (50% -> 70% -> 80% -> 90% -> 95%-> 100% -> 100%) for 15 minutes each, then tissues substituted with t-butyl alcohol followed by freeze drying. Before mounting samples, tumors were cut on the sagittal plane to reveal the tumor core then mounted onto aluminum stubs and were metal-coated using a magnetron sputter (MSP-1S; Vacuum Device), and examined by scanning electron microscopy (VE-7800; Keyence).
RNA isolation
RNA was isolated using Qiagen RNeasy Mini kits, as per manufacturer instructions. Briefly, tissue stored in -80°C was placed in buffer RLT + b-mercaptoethanol and homogenized by bead beating. Lysates were then processed as recommended, with the optional DNase digest.
RNA was quantified using a DeNovix DS-11.
cDNA library prep and RNA sequencing RNA integrity was assessed by Agilent Bioanalyzer before proceeding RIN values of 8 or greater were used. 2 ug of RNA was used to prepare a cDNA library using TruSeq RNA
Library Prep Kit v2 (Illumina). Sequencing was performed on an Illumina HiSeq 1500
System in a 1 x 50 bp single read mode. Sequenced reads were mapped against the mouse reference genome (mm10) using TopHat (48) , and gene expression was quantified by Cufflinks (49) . Gene ontology enrichment analysis was performed using DAVID (29, 30) . After adding the derivatization agent, samples were shaken at 1,200 rpm for 90 min at 30°C.
Samples were then silylated with 20 μl of N-methyl-N-trimethylsilyl-trifluoroacetamide (GL Science) for 30 min at 37°C with shaking at 1,200 rpm. After derivatization, samples were centrifuged at 16,000 × g for 5 min at room temperature, and the supernatant transferred to glass vial for gas chromatography-tandem mass spectrometry measurement using a GCMS-TQ8030 triple quadrupole mass spectrometer (Shimadzu) with a capillary column (BPX5, SGE Analytical Science). The GC program was previously described (50) . Data processing was performed using LabSolutions Insight (Shimadzu).
The quantified metabolome data was statistically analyzed using Orthogonal Partial Least 
Tumor organoid establishment and culture
Tumor organoids were established as previously described (51), with some alterations.
Buffers and culture medium components are listed in Table 2 . Tumors were dissected from the colons of mice that had CAC-induced tumors and from the SI and colon of Apc min/+ mice.
Tumors were washed in cold PBS then incubated in 10 mL chelation buffer with 2mM EDTA for 60 mins on ice. Tubes were shaken vigorously by hand (removes most normal epithelium) and EDTA buffer was removed and tumor tissue then washed 3x with chelation buffer.
Tissue was then incubated in digestion buffer for 30 minutes at 37°C with shaking.
Supernatant was filtered through a 70 µM filter, remaining tissue wash once with basic medium and also filtered. Cells were then pelleted (300 g for 3 minutes) washed once then resuspended in Matrigel (Corning 356231) (50 uL per well) and cultured in 24-well plate with 500 µL complete medium. Once established for 1 to 2 weeks, cultures were switched to EGF-only medium.
For maintenance, organoids were split every week. In brief, all tubes and tips were pre-coated with FBS, organoids were manually disrupted from the Matrigel using P500 pipette and transferred to a 50 mL Falcon tube. Tubes were centrifuged at 300 g for 5 mins at 4 deg.
Excess medium was removed carefully to not removed Matrigel containing the cell pellet.
Organoids were resuspended in 4 mL Basic medium, transferred to a 15 mL tube and pipetted thoroughly using a fire-polished glass pipette to break up the organoids. These were centrifuged and resuspended in Matrigel and plated out. Split ratios of around 1:4 to 1:6 depending on density. Tumor organoids were infected at day 5 post-split to ensure good organoid size and integrity.
STm ∆aroA was grown overnight and sub-cultured as described above. 5 µL containing 1x10 8 CFU was dropped into the culture medium (or PBS control) and left for 2 hrs to allow for bacterial invasion of the Matrigel and organoids. After 2 hrs medium was removed and Matrigel washed 2x with PBS and medium replaced and gentamycin added. These were cultured overnight and organoids collected 24 hrs after initial infection for analysis. For qPCR analysis, buffer RLT was added directly to the culture plate (after removing medium and washing with PBS) which completely dissolved the Matrigel, these were then processed for RNA isolation as described above. For metabolome and succinate assays, culture medium was removed and the Matrigel washed with PBS. BD Cell Recovery Solution was added and plate kept on ice for 1 hr to dissolve the Matrigel. Organoids were collected into Eppendorf tubes spun and washed twice with cold PBS. Organoids were then snap frozen and stored at -20 until analysis.
Heat killed STm ∆aroA was prepared by incubating at 95°C for 5 minutes. Effective killing was tested by plating out on LB agar. SN was prepared by growing STm ∆aroA in tumor culture medium until an OD600 of approximately 0.7. SN was filtered with a 10 kDa cut-off columns. 1x10 5 heat-killed STm ∆aroA were used as this is the average CFU count obtained from the live infections after 24 hours, and the amount of SN added was also calculated based on this CFU.
Succinate Assay
Succinate assay (Sigma) was performed on cell lysates as per the manufacturers protocol and 96-well plates were measured on a spectrophotometer (Spectrostar Nano -BMG Labtech) at the respective wavelengths. 
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